India is debating the introduction of data exclusivity in pharmaceuticals, a regulatory protection that can delay the entry of generic drugs even after patent expiry. While the move is projected as a way to attract investment and support innovation, it raises serious concerns for India’s generics-driven pharmaceutical industry and access to affordable medicines. In the absence of any international obligation under WTO-TRIPS, the policy choice involves balancing innovation incentives with public health priorities and preserving India’s role as the pharmacy of the developing world.
Click to View MorePollution is emerging as a hidden reproductive health crisis, as toxins in air, water, soil and plastics disrupt hormones, damage sperm and egg quality, and increase miscarriage and poor birth outcomes. Evidence from India and globally shows declining fertility, particularly in polluted cities, indicating that cleaner environments are essential for protecting family health and demographic stability.
Click to View More
© 2026 iasgyan. All right reserved